Option Care Health (NASDAQ:OPCH) Sees Strong Trading Volume

Option Care Health, Inc. (NASDAQ:OPCH - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 1,565,199 shares traded hands during trading, an increase of 27% from the previous session's volume of 1,232,796 shares.The stock last traded at $30.46 and had previously closed at $30.41.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on OPCH shares. Jefferies Financial Group increased their price target on shares of Option Care Health from $36.00 to $38.00 and gave the company a "buy" rating in a research report on Monday, March 4th. Barrington Research increased their price target on shares of Option Care Health from $35.00 to $38.00 and gave the company an "outperform" rating in a research report on Friday, February 23rd.

Option Care Health Stock Performance

The company's 50-day moving average price is $32.19 and its 200 day moving average price is $31.53. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.33 and a current ratio of 1.77. The stock has a market capitalization of $5.32 billion, a PE ratio of 20.81, a PEG ratio of 1.77 and a beta of 1.22.

Option Care Health (NASDAQ:OPCH - Get Free Report) last posted its earnings results on Thursday, February 22nd. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.29 by $0.03. Option Care Health had a net margin of 6.21% and a return on equity of 18.78%. The firm had revenue of $1.12 billion during the quarter, compared to analysts' expectations of $1.09 billion. During the same period last year, the company posted $0.26 EPS. The company's quarterly revenue was up 9.5% compared to the same quarter last year. On average, equities research analysts expect that Option Care Health, Inc. will post 1.13 earnings per share for the current fiscal year.

Insider Activity at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. purchased 35,000 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was bought at an average cost of $31.55 per share, with a total value of $1,104,250.00. Following the transaction, the director now directly owns 269,528 shares in the company, valued at approximately $8,503,608.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.64% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Park Place Capital Corp increased its stake in Option Care Health by 48.4% during the 1st quarter. Park Place Capital Corp now owns 1,140 shares of the company's stock valued at $38,000 after purchasing an additional 372 shares in the last quarter. Vontobel Holding Ltd. increased its stake in Option Care Health by 2.9% during the 3rd quarter. Vontobel Holding Ltd. now owns 13,168 shares of the company's stock valued at $426,000 after purchasing an additional 374 shares in the last quarter. Parallel Advisors LLC increased its stake in Option Care Health by 130.2% during the 4th quarter. Parallel Advisors LLC now owns 845 shares of the company's stock valued at $28,000 after purchasing an additional 478 shares in the last quarter. Securian Asset Management Inc. grew its stake in shares of Option Care Health by 3.4% in the third quarter. Securian Asset Management Inc. now owns 15,235 shares of the company's stock worth $493,000 after acquiring an additional 503 shares during the period. Finally, Sheets Smith Wealth Management raised its holdings in shares of Option Care Health by 1.6% during the third quarter. Sheets Smith Wealth Management now owns 32,542 shares of the company's stock valued at $1,053,000 after purchasing an additional 510 shares during the last quarter. 98.05% of the stock is owned by hedge funds and other institutional investors.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.